This is a working overview of visceral fat, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-20. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
=== Caffeine === Caffeine is the most widely consumed stimulant in North America. Caffeine causes the release of epinephrine from the adrenal medulla. In small doses, caffeine can improve endurance. It has also been shown to delay the onset of fatigue in exercise. The most probable mechanism for the delay of fatigue is through the obstruction of adenosine receptors in the central nervous system. Adenosine is a neurotransmitter that decreases arousal and increases sleepiness. By preventing adenosine from acting, caffeine removes a factor that promotes rest, and delays fatigue.
== Sources == Crick, Francis (1990). What Mad Pursuit: a Personal View of Scientific Discovery (reprint ed.). New York: Basic Books. ISBN 0-465-09138-5. Maddox, Brenda (2002). Rosalind Franklin: the dark lady of DNA. London: HarperCollins. ISBN 0-06-018407-8. Olby, Robert (2009). Francis Crick: Hunter of Life's Secrets. Cold Spring Harbor Laboratory Press. ISBN 978-0-87969-798-3. Ridley, Matt (2006). Francis Crick: Discoverer of the Genetic Code. Ashland, OH: Atlas Books. ISBN 0-06-082333-X. Wilkins, Maurice (2003). The Third Man of the Double Helix: The Autobiography of Maurice Wilkins. Oxford University Press. ISBN 0-19-860665-6.
PC Zone gave a rating of three out of five. Opposing Force CTF – A capture the flag mod based on Gearbox Software's expansion pack Half-Life: Opposing Force that was originally released in Half-Life patch 1.1.0.0. A standalone version was released a few months later. Oz Deathmatch – An early serverside mod that is a collection of deathmatch configuration options. Options that can be changed include magazine size, amount of blood, and weapon recoil. The mod also adds a new gadget, a grappling hook. The mod also supports Team Fortress Classic maps. In January 2000, it was listed among the top five HL mods on GameSpy's server browser. CNET Gamecenter placed it on its list of top 10 Half-Life mods, writing: "Oz has long been one of our favorite ways to deathmatch." Ricochet – An official Half-Life mod by Valve. It was released on November 1, 2000, and included in Half-Life's version 1.1.1.0 update, released on June 12, 2002. Ports of the game to OS X and Linux were released through Steam on August 1, 2013. Rocket Crowbar – An early mod that modifies every weapon in the game. For example the crowbar shoots "drunk" rockets and RPG shoots scientist and Barney modelled proximity mines. The mod also includes a capture the flag mode. Rocket Crowbar Redux: Source, was released for the Source engine. It includes weapons like gravity grenade and a scientist shotgun. Runaway Train – Similar to the game king of the hill, one player is on a train, the other players try to knock them off of it. The longer the player stays on the train, the more points they score.
Sources: en.wikipedia.org
== External links == History of Mass Spectrometry - Pioneers - University of New South Wales Sydney Five Mass Spectrometry Nobel Prize Pioneers - Bristol University History of Mass Spectrometry - Scripps Institute
== Regulation == The rate of hormone biosynthesis and secretion is often regulated by a homeostatic negative feedback control mechanism. Such a mechanism depends on factors that influence the metabolism and excretion of hormones. Thus, higher hormone concentration alone cannot trigger the negative feedback mechanism. Negative feedback must be triggered by overproduction of an "effect" of the hormone.
In Peru, this manifests in the worship of Pachamama, the earth and fertility goddess, who symbolizes the close connection to nature and reflects the collective unconscious of Andean culture. Canadian black metal band Panzerfaust used the Jungian concept of the 'Shadow' in the title of their 2024 record "To Shadow Zion"
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.